Rosuvastatin max dose
Pro Research Analysisby 
Searched over 200M research papers
Maximum Dose of Rosuvastatin: Insights from Research
Introduction to Rosuvastatin and Its Uses
Rosuvastatin is a potent statin used to manage dyslipidemia by inhibiting the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, which is crucial for cholesterol synthesis in the liver 12. It is commonly prescribed to lower low-density lipoprotein cholesterol (LDL-C) and improve overall lipid profiles in patients with hypercholesterolemia and other cardiovascular risk factors 45.
Pharmacokinetics and Dose Proportionality
Research indicates that rosuvastatin exhibits dose-proportional pharmacokinetics over a range of doses. In a study involving healthy volunteers, single doses of 10, 20, 40, and 80 mg of rosuvastatin showed a linear relationship between dose and systemic exposure, as measured by maximum plasma concentration (C_max) and area under the plasma concentration-time curve (AUC) 1. This dose proportionality suggests that higher doses result in proportionally higher plasma concentrations of the drug.
Maximum Approved Dose
The maximum approved daily dose of rosuvastatin is 40 mg 2. This dosage has been shown to produce significant reductions in LDL-C and other lipid parameters, making it highly effective for patients requiring intensive lipid-lowering therapy 57. Studies have demonstrated that rosuvastatin 40 mg can achieve greater reductions in LDL-C compared to maximum doses of other statins like atorvastatin and simvastatin 5.
Safety and Tolerability
The safety profile of rosuvastatin at doses up to 40 mg is comparable to other statins. In clinical trials, adverse events were similar across different statins, with myopathy and elevated liver enzymes occurring at low rates 7. However, doses above 40 mg, such as 80 mg, have been associated with higher systemic exposure and potential for increased adverse effects, which is why 40 mg is the highest approved dose for clinical use 17.
Special Populations and Considerations
Pharmacokinetic studies have shown that systemic exposure to rosuvastatin can be higher in certain populations, such as Asian subjects, compared to Caucasians 310. This necessitates careful consideration of dosing in these populations to avoid excessive drug exposure and potential toxicity.
Conclusion
Rosuvastatin is a highly effective statin for managing dyslipidemia, with a maximum approved daily dose of 40 mg. This dose provides significant lipid-lowering benefits while maintaining a favorable safety profile. Higher doses, such as 80 mg, are not recommended due to increased risk of adverse effects. Clinicians should consider individual patient characteristics, including ethnicity, when prescribing rosuvastatin to ensure optimal efficacy and safety.
Sources and full results
Most relevant research papers on this topic
A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
Rosuvastatin systemic exposure is dose proportional in healthy men at doses of 10 to 80 mg, with well-tolerated results in this study.
RCTPharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults
Rosuvastatin's pharmacokinetics vary significantly between races, with potential clinical relevance in drug interactions with darunavir/ritonavir and erythromycin.
Systematic Review
Rigorous JournalPharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
Rosuvastatin pharmacokinetics are similar to those of healthy Chinese subjects living in China, with minimal accumulation and no significant differences in pharmacokinetic parameters between Asian and Western subjects.
RCTEfficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
Rosuvastatin effectively reduced LDL-C levels more than pravastatin or simvastatin in patients with hypercholesterolemia, with more patients achieving their ATP II LDL-C goals.
RCT
Large Human Trial
Highly CitedDoses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis
Rosuvastatin doses are equivalent to 3–3.5 times higher atorvastatin and 7–8 times higher simvastatin doses for achieving equal reductions in LDL-C and non-HDL-C levels.
Meta-AnalysisOnce-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance.
Rosuvastatin once a week is well tolerated and leads to significant lipoprotein changes in patients with a history of statin intolerance.
Non-RCTHighly CitedBenefit-risk assessment of Rosuvastatin 10 to 40 milligrams.
Rosuvastatin 10 to 40 mg has a very favorable benefit-risk profile, reducing LDL cholesterol and improving various lipid measures while maintaining similar adverse event profiles to other statins.
Non-RCTLarge Human TrialHighly CitedEffect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension.
Both low (5 mg/day) and high (20-40 mg/day) rosuvastatin doses improve arterial stiffness and NAFLD, but the high dose is more effective in reducing PWVs and central haemodynamics.
RCTEffect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis
High-dose rosuvastatin loading before percutaneous coronary intervention significantly reduces hs-CRP levels, improves cholesterol levels, and increases HDL-C levels in Chinese patients with acute coronary syndrome.
Meta-AnalysisRigorous JournalPharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
Rosuvastatin has dose proportionality and pharmacokinetic properties similar to those of other statins, with no significant differences between sexes or fasted and fed states.
RCT